Nevirapine Teva

Nevirapine, the active ingredient in Nevirapine Teva, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as a tablet for oral use. It treats HIV-1 infection in adults and children. GNH USA supplies Nevirapine Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication used in the treatment of HIV-1 infection.

HIV-1 infection (adults): reduces viral load when combined with other antiretrovirals. HIV-1 infection (children): part of pediatric combination therapy to control disease progression. Treatment‑experienced HIV-1 patients: offers an alternative NNRTI option when resistance patterns allow.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Fatigue: feeling of tiredness or weakness. - Headache: transient cranial discomfort. - Abdominal pain: mild stomach discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Hepatic failure: significant liver injury with elevated enzymes. - Severe hypersensitivity: systemic allergic response with fever and malaise. - Liver toxicity: jaundice or hepatitis. - Severe neutropenia: marked reduction in white blood cells. - Life‑threatening skin reactions: toxic epidermal necrolysis.

When prescribing Nevirapine, clinicians should observe several safety measures.

Liver function monitoring: assess baseline and periodic liver enzymes due to risk of hepatotoxicity. Skin reactions: discontinue if severe rash or Stevens‑Johnson syndrome develops. Drug resistance: avoid monotherapy; use only in combination regimens. Pregnancy: evaluate risk‑benefit; use only if benefits outweigh potential fetal risks. Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Nevirapine interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may increase nevirapine levels and toxicity. - St. John’s wort: induces metabolism, reducing nevirapine effectiveness. - Efavirenz: combined use may heighten hepatotoxic risk. - Azole antifungals (e.g., ketoconazole): can raise nevirapine concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., certain statins): may require dose adjustment. - Oral contraceptives: efficacy may be reduced; consider alternative contraception. - Methadone: nevirapine may lower methadone levels, necessitating monitoring.